- $209.29m
- $144.98m
- $83.79m
- 45
- 28
- 87
- 53
Annual cashflow statement for Pulmonx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -32.2 | -48.7 | -58.9 | -60.8 | -56.4 |
| Depreciation | |||||
| Non-Cash Items | 5.9 | 14.3 | 19.3 | 24.2 | 25.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.79 | -7.85 | -7.01 | -2.56 | -1.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -30.6 | -41.4 | -45.1 | -37.6 | -31.5 |
| Capital Expenditures | -0.911 | -3.67 | -1.32 | -0.807 | -1.45 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 13.6 | -42.6 | -2.91 | -1.2 | 18.9 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 12.7 | -46.3 | -4.22 | -2.01 | 17.5 |
| Financing Cash Flow Items | -4.5 | -0.041 | -0.053 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 235 | 4.46 | 2.42 | 21.4 | 1.36 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 217 | -83.1 | -46.7 | -18.2 | -12.6 |